We are live on
!
Find out more
SEC
Seven Eight Capital Portfolio holdings
AUM
$1.11B
1-Year Est. Return
29.48%
This Fund
S&P 500
This Quarter
Est. Return
-6.56%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$855M
AUM Growth
+$250M
(+41%)
Cap. Flow
+$327M
Cap. Flow
% of AUM
38.29%
Top 10 Holdings %
Top 10 Hldgs %
13.1%
Holding
788
New
316
Increased
155
Reduced
106
Closed
211
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$13.6M |
| 2 |
Merck
MRK
|
+$12.5M |
| 3 |
Intuitive Surgical
ISRG
|
+$11.1M |
| 4 |
DOCU
DocuSign
DOCU
|
+$10.9M |
| 5 |
Insulet
PODD
|
+$10.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nasdaq
NDAQ
|
+$7.26M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$6.86M |
| 3 |
Incyte
INCY
|
+$6.31M |
| 4 |
Fidelity National Information Services
FIS
|
+$5.73M |
| 5 |
AbbVie
ABBV
|
+$4.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.41% |
| 2 | Consumer Discretionary | 17.68% |
| 3 | Healthcare | 16.13% |
| 4 | Industrials | 12.13% |
| 5 | Financials | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
CoStar Group
CSGP
$12.2B
| $606K | 0.07% |
+7,881
| New | +$653K |
|
352
Intellia Therapeutics
NTLA
$1.53B
| $606K | 0.07% |
19,158
+7,549
| +65% | +$293K |
|
353
JB Hunt Transport Services
JBHT
$25.6B
| $605K | 0.07% |
+3,210
| New | +$617K |
|
354
Mercury Systems
MRCY
$6.45B
| $601K | 0.07% |
+16,208
| New | +$598K |
|
355
InMode
INMD
$874M
| $598K | 0.07% |
19,639
-12,042
| -38% | -$473K |
|
356
Axos Financial
AX
$5.89B
| $596K | 0.07% |
+15,750
| New | +$666K |
|
|
DVAX
357
DELISTED
Dynavax Technologies
DVAX
| $591K | 0.07% |
+40,029
| New | +$563K |
|
358
Insperity
NSP
$1.95B
| $583K | 0.07% |
+5,976
| New | +$625K |
|
359
Copart
CPRT
$26.8B
| $580K | 0.07% |
13,466
+3,462
| +35% | +$154K |
|
360
Live Nation Entertainment
LYV
$42.8B
| $578K | 0.07% |
+6,963
| New | +$607K |
|
361
Flowers Foods
FLO
$1.57B
| $574K | 0.07% |
25,860
+13,177
| +104% | +$316K |
|
362
Gates Industrial Corporation Ltd.
GTES
$7.42B
| $572K | 0.07% |
+49,288
| New | +$613K |
|
363
AutoNation
AN
$7.13B
| $572K | 0.07% |
3,775
-3,404
| -47% | -$543K |
|
364
Extreme Networks
EXTR
$3.43B
| $569K | 0.07% |
23,508
+14,009
| +147% | +$379K |
|
365
Franco-Nevada
FNV
$43.7B
| $566K | 0.07% |
4,238
+1,845
| +77% | +$261K |
|
366
Diamondback Energy
FANG
$52.4B
| $561K | 0.07% |
3,620
+1,548
| +75% | +$228K |
|
367
Scorpio Tankers
STNG
$3.71B
| $559K | 0.07% |
+10,335
| New | +$505K |
|
|
SKX
368
DELISTED
Skechers
SKX
| $558K | 0.07% |
11,409
-34,628
| -75% | -$1.77M |
|
|
BECN
369
DELISTED
Beacon Roofing Supply, Inc.
BECN
| $557K | 0.07% |
7,222
+3,131
| +77% | +$253K |
|
|
GES
370
DELISTED
Guess Inc
GES
| $555K | 0.06% |
+25,659
| New | +$542K |
|
371
Winnebago Industries
WGO
$904M
| $555K | 0.06% |
+9,338
| New | +$605K |
|
372
American International
AIG
$42.5B
| $550K | 0.06% |
+9,084
| New | +$542K |
|
373
Idexx Laboratories
IDXX
$46.1B
| $549K | 0.06% |
+1,255
| New | +$626K |
|
374
Ametek
AME
$58.4B
| $548K | 0.06% |
3,708
+245
| +7% | +$38.3K |
|
|
CTRA
375
DELISTED
Coterra Energy
CTRA
| $542K | 0.06% |
20,034
-12,240
| -38% | -$334K |
|
Similar funds
PP
ECM
GCAC
CAM
D
GFS
FTIS
AIA
Seven Eight Capital's Q3 2023 Portfolio in Review
As of Q3 2023, Seven Eight Capital held 788 positions worth $855M, up 41% from $605M the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Seven Eight Capital deployed $327M of net new capital in Q3 2023, opening 316 new positions and adding to 155 existing holdings. Its largest new stake was Merck: 115,677 shares worth $11.9M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $6.86M trimmed.
- Seven Eight Capital's largest Q3 2023 buy was Merck: 115,677 shares worth $11.9M.
- Seven Eight Capital added most to Edwards Lifesciences in Q3 2023, an estimated $13.6M increase.
- Seven Eight Capital's biggest Q3 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $6.86M.
- Seven Eight Capital fully exited Nasdaq in Q3 2023, selling an estimated $7.26M.
- Seven Eight Capital's ten largest holdings make up 13% of its $855M portfolio in Q3 2023.
- Seven Eight Capital opened 316 new positions and closed 211 in Q3 2023.
- Seven Eight Capital's portfolio value rose 41% quarter-over-quarter to $855M.
Based on Seven Eight Capital's 13F filing for Q3 2023, filed 14 Nov 2023.